Guggenheim analyst Michael Schmidt downgraded Arvinas to Neutral from Buy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Arvinas price target lowered to $27 from $43 at Wedbush
- Arvinas price target lowered to $95 from $102 at Oppenheimer
- Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
- Wells Fargo downgrades Arvinas to Equal Weight, lowers price target to $49
- Barclays views GSK acquisition interest as positive for oncology stocks